Clinical Trial Update: Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation [Phase 2]

View source ↗

Summary

Phase 2 pilot trial assessing safety, pharmacokinetics, and iron chelating activity of DST-0509 (Deferasirox) in thalassemia major patients refractory to chelat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia Major

Drugs mentioned

• DST-0509 (Deferasirox) (Deferasirox)

Snippet

Sponsor: DisperSol Technologies, LLC | Conditions: Thalassemia Major | Phase 2 | Status: COMPLETED